Drug intelligence / Profile preview

adalimumab + golimumab

Development stage: Unknown
Lead developer: Janssen Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

This represents a combination of two separate TNF-alpha inhibitors. Adalimumab (Humira) and golimumab (Simponi) are both fully human monoclonal antibodies that target and inhibit tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory cytokine involved in various inflammatory conditions. Both medications are used to treat conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. They work by binding to TNF-alpha and preventing it from interacting with cell surface receptors, thereby reducing inflammation.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on adalimumab + golimumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adalimumab + golimumab.

Explore the full profile